Gerardo Hernandez Sells 7,236 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 7,236 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the transaction, the chief financial officer owned 14,689 shares of the company’s stock, valued at $2,162,367.69. This trade represents a 33.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Gerardo Hernandez also recently made the following trade(s):

• On Monday, March 2nd, Gerardo Hernandez sold 375 shares of TransMedics Group stock. The shares were sold at an average price of $139.12, for a total value of $52,170.00.
• On Thursday, December 4th, Gerardo Hernandez sold 920 shares of TransMedics Group stock. The shares were sold at an average price of $139.62, for a total value of $128,450.40.

TransMedics Group Stock Down 5.1%

Shares of NASDAQ:TMDX opened at $140.07 on Friday. The company’s fifty day moving average is $135.24 and its 200-day moving average is $126.87. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. TransMedics Group, Inc. has a 52 week low of $62.07 and a 52 week high of $156.00. The company has a market capitalization of $4.80 billion, a PE ratio of 28.59 and a beta of 1.98.

Analyst Ratings Changes

Several analysts have recently weighed in on TMDX shares. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Needham & Company LLC raised their price target on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. lifted their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Oppenheimer raised their target price on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group News Summary

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Wall‑street support — several firms recently raised price targets and maintained buy/overweight ratings, which boosts headline upside and institutional interest. MarketBeat Analyst Coverage
• Positive Sentiment: Technical setup — Investors.com flags a cup‑with‑handle with a buy point at $151.85; a decisive breakout above that level could trigger momentum buying and validate the technical thesis. Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge
• Neutral Sentiment: Institutional backing — large positions from Vanguard, UBS, Goldman and others mean strong liquidity and long‑term holders, which can stabilize shares but don’t eliminate short‑term swings. MarketBeat Institutional Holdings
• Negative Sentiment: Insider selling — multiple insiders including CFO Gerardo Hernandez sold sizeable blocks this week (notably a 7,236‑share sale at ~$147.21 on Mar 4 plus other disposals), and other insiders trimmed positions; concentrated insider exits are likely a near‑term headwind for sentiment. TransMedics Group (NASDAQ:TMDX) CFO Sells $52,170.00 in Stock

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. boosted its position in shares of TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new position in TransMedics Group during the third quarter worth about $28,000. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group during the third quarter worth about $29,000. Allworth Financial LP grew its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. Finally, Optiver Holding B.V. increased its holdings in shares of TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.